Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report

Crizotinib, the first clinically available inhibitor of anaplastic lymphoma kinase (ALK) gene rearrangement, is generally well tolerated. In contrast, neutropenia induced by crizotinib is a commonly reported grade 3 or 4 adverse event. In such cases, interruption and dose reduction of crizotinib mig...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Case Rep Oncol
Autors principals: Osugi, Jun, Owada, Yuki, Yamaura, Takumi, Muto, Satoshi, Okabe, Naoyuki, Matsumura, Yuki, Higuchi, Mitsunori, Suzuki, Hiroyuki, Gotoh, Mitsukazu
Format: Artigo
Idioma:Inglês
Publicat: S. Karger AG 2016
Matèries:
Published online: January, 2016
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4748772/
https://ncbi.nlm.nih.gov/pubmed/26933419
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000443662
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars